Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 14/20 | 0.46 |
| ▸ | SLC2A3 | P11169 | 14/20 | 0.46 |
| ▸ | SLC2A4 | P14672 | 14/20 | 0.46 |
| ▸ | SLC2A2 | P11168 | 6/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | CPT1A | P50416 | 2/20 | 0.41 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12885227 | 1.00 | CNR1 (0.54) | CNR1CNR2SLC2A1SLC2A3SLC2A4 | |
| SCHEMBL12885569 | 0.93 | CNR1 (0.54) | CNR1CNR2SLC2A1SLC2A3SLC2A4 | |
| SCHEMBL1214533 | 0.92 | CNR1 (0.62) | CNR1CNR2PTGER4CPT1ACPT1B | |
| SCHEMBL12885239 | 0.92 | CNR1 (0.62) | CNR1CNR2PTGER4CPT1ACPT1B | |
| SCHEMBL12885932 | 0.90 | CNR1 (0.49) | CNR1CNR2SLC2A1SLC2A3SLC2A4 | |
| SCHEMBL12885236 | 0.90 | CNR1 (0.47) | CNR1CNR2SLC2A1SLC2A3SLC2A4 | |
| SCHEMBL1215748 | 0.90 | CNR1 (0.47) | CNR1CNR2SLC2A1SLC2A3SLC2A4 | |
| SCHEMBL13688896 | 0.89 | CNR1 (0.57) | CNR1CNR2PTGER4CPT1ACPT1B | |
| SCHEMBL1217555 | 0.88 | CNR1 (0.56) | CNR1CNR2SLC2A1SLC2A3SLC2A4 | |
| SCHEMBL12885229 | 0.88 | CNR1 (0.56) | CNR1CNR2SLC2A1SLC2A3SLC2A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028447-A1 | INDAZOLE DERIVATIVES | PFIZER INC. | 2011-02-03 | — | — | US | claimed |
| US-20110028447-A1 | INDAZOLE DERIVATIVES | PFIZER INC. | 2011-02-03 | — | — | US | disclosed |
| EP-2265335-A1 | INDAZOLE DERIVATIVES | Pfizer Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009106982-A1 | INDAZOLE DERIVATIVES | PFIZER INC. (US) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028447-A1 | INDAZOLE DERIVATIVES | CNR1, CNR2, GPR119 | CNR1 1/4885CNR2 2/4885SLC2A1 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.